Fidelity SPDR Advertisement
Home > Boards > US Listed > Biotechs > Arena Pharmaceuticals, Inc. (ARNA)

orexigen is no compensation at this point whatsoever period.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
lovethatgreen Member Profile
Member Level 
Followed By 192
Posts 20,341
Boards Moderated 1
Alias Born 08/07/04
160x600 placeholder
Arena Pharmaceuticals Issued Composition of Matter Patent by United States Patent and Trademark Office for Ralinepag and Rela... "PR Newswire (US)" - 11/25/2014 8:00:00 AM
Arena Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference "PR Newswire (US)" - 11/24/2014 8:00:00 AM
Arena Pharmaceuticals to Present at Stifel 2014 Healthcare Conference "PR Newswire (US)" - 11/13/2014 8:00:00 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 11/6/2014 4:57:53 PM
Lorcaserin HCl Data to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases "PR Newswire (US)" - 11/6/2014 8:00:00 AM
Arena Pharmaceuticals to Present at Credit Suisse 2014 Healthcare Conference "PR Newswire (US)" - 11/5/2014 8:00:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 11/3/2014 7:31:36 AM
Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2014 Financial Results "PR Newswire (US)" - 11/3/2014 6:45:00 AM
Eisai and Arena Pharmaceuticals Report Results of an Investigational Phase 2 Trial of Lorcaserin HCl as an Aid for Smoking Ce... "PR Newswire (US)" - 11/3/2014 6:30:00 AM
Lorcaserin Data to be Presented at The Obesity Society's Annual Scientific Meeting "PR Newswire (US)" - 10/31/2014 8:37:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 10/30/2014 9:19:06 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 10/30/2014 6:03:00 AM
Eisai and Arena Pharmaceuticals Report Results of an Investigational Pilot Study of Coadministration of Lorcaserin HCl and Ph... "PR Newswire (US)" - 10/28/2014 6:20:00 PM
Arena Pharmaceuticals Announces Third Quarter 2014 Conference Call and Webcast on Monday, November 3 "PR Newswire (US)" - 10/27/2014 8:00:00 AM
Eisai and Arena Pharmaceuticals Announce Presentation of Lorcaserin HCl Data at the American College of Clinical Pharmacy Ann... "PR Newswire (US)" - 10/13/2014 8:00:00 AM
Eisai and Arena Pharmaceuticals Announce Publication of Pooled Phase 3 Clinical Trial Analysis of BELVIQ® (lorcaserin HCl) C... "PR Newswire (US)" - 10/10/2014 11:36:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 10/9/2014 4:41:48 PM
Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference "PR Newswire (US)" - 9/22/2014 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 9/19/2014 4:49:54 PM
FDA Approves Orexigen's Diet Drug Contrave "Dow Jones News" - 9/11/2014 8:50:11 AM
Lorcaserin HCl Data to be Presented at the American Society of Bariatric Physicians' 64th Annual Obesity & Associated Conditi... "PR Newswire (US)" - 9/10/2014 8:00:00 AM
Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension "PR Newswire (US)" - 9/2/2014 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 8/27/2014 7:52:46 PM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 8/6/2014 4:34:28 PM
lovethatgreen Member Level  Monday, 05/14/12 08:57:20 AM
Re: gixxer11 post# 4348
Post # of 21626 
orexigen is no compensation at this point whatsoever period.

and vvus at the stage theyre at, is at a disadvantage in several ways

no manufacturing set up....the risks with the drug are numerous combined with detox requirements after 90 days

I could go on

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist